Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.

Abstract:

:The extent of genetic variation found in drug metabolism genes and its contribution to interindividual variation in response to medication remains incompletely understood. To better determine the identity and frequency of variation in 11 phase I drug metabolism genes, the exons and flanking intronic regions of the cytochrome P450 (CYP) isoenzyme genes CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5 were amplified from genomic DNA and sequenced. A total of 60 kb of bi-directional sequence was generated from each of 93 human DNAs, which included Caucasian, African-American and Asian samples. There were 388 different polymorphisms identified. These included 269 non-coding, 45 synonymous and 74 non-synonymous polymorphisms. Of these, 54% were novel and included 176 non-coding, 14 synonymous and 21 non-synonymous polymorphisms. Of the novel variants observed, 85 were represented by single occurrences of the minor allele in the sample set. Much of the variation observed was from low-frequency alleles. Comparatively, these genes are variation-rich. Calculations measuring genetic diversity revealed that while the values for the individual genes are widely variable, the overall nucleotide diversity of 7.7 x 10(-4) and polymorphism parameter of 11.5 x 10(-4) are higher than those previously reported for other gene sets. Several independent measurements indicate that these genes are under selective pressure, particularly for polymorphisms corresponding to non-synonymous amino acid changes. There is relatively little difference in measurements of diversity among the ethnic groups, but there are large differences among the genes and gene subfamilies themselves. Of the three CYP subfamilies involved in phase I drug metabolism (1, 2, and 3), subfamily 2 displays the highest levels of genetic diversity.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Solus JF,Arietta BJ,Harris JR,Sexton DP,Steward JQ,McMunn C,Ihrie P,Mehall JM,Edwards TL,Dawson EP

doi

10.1517/14622416.5.7.895

keywords:

subject

Has Abstract

pub_date

2004-10-01 00:00:00

pages

895-931

issue

7

eissn

1462-2416

issn

1744-8042

pii

PGS050712

journal_volume

5

pub_type

杂志文章
  • Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.

    abstract::Abacavir is an effective antiretroviral drug used to treat HIV-1 infection. Approximately 5% of patients treated with abacavir develop a hypersensitivity reaction that requires discontinuation of the drug. In an initial pharmacogenetic study conducted in a predominantly White male population, multiple markers in the h...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,多中心研究

    doi:10.1517/phgs.5.2.203.27481

    authors: Hughes AR,Mosteller M,Bansal AT,Davies K,Haneline SA,Lai EH,Nangle K,Scott T,Spreen WR,Warren LL,Roses AD,CNA30027 Study Team.,CNA30032 Study Team.

    更新日期:2004-03-01 00:00:00

  • miRNAs: from neurogeneration to neurodegeneration.

    abstract::miRNAs are reported to sequence-specifically control the translation of target mRNAs by binding to 3 UTRs. The abundant expression of miRNAs in the brain highlights their biological significance in neurodevelopment. Many studies have shown that miRNAs are involved in a variety of functions, including developmental tra...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.8.971

    authors: Singh SK

    更新日期:2007-08-01 00:00:00

  • Pharmacogenomics of episodic migraine: time has come for a step forward.

    abstract::Migraine is characterized by heterogeneous behavior in response to drugs. Many resources have been invested in attempting to unravel the genetic basis of migraine, while the role of genetics in responses to currently available drugs has received less attention. We performed a systematic literature search identifying o...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.20

    authors: Viana M,Terrazzino S,Genazzani AA,Grieco GS,Cargnin S,Santorelli FM,Pierelli F,Tassorelli C,Nappi G,Di Lorenzo C

    更新日期:2014-03-01 00:00:00

  • The genetics of fibromyalgia syndrome.

    abstract::Fibromyalgia syndrome (FMS) is a common chronic widespread pain syndrome mainly affecting women. Although the etiology of FMS is not completely understood, varieties of neuroendocrine disturbances, as well as abnormalities of autonomic function, have been implicated in its pathogenesis. The exposure of a genetically p...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.1.67

    authors: Buskila D,Sarzi-Puttini P,Ablin JN

    更新日期:2007-01-01 00:00:00

  • Investigation of the impact of an ADCY2 polymorphism as a predictive biomarker in bipolar disorder, suicide tendency and response to lithium carbonate therapy: the first report from Iran.

    abstract::High rates of mortality due to both suicide and medical comorbidities in bipolar patients can be decreased through the administration of lithium, which affects the cerebral endothelium as well as neurons. To investigate the role of ADCY2 in risk of bipolar disorder, we genotyped the ADCY2 rs2290910 in bipolar patients...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0058

    authors: Aghabozorg Afjeh SS,Shams J,Hamednia S,Boshehri B,Olfat A,Omrani MD

    更新日期:2020-09-01 00:00:00

  • Cell-free DNA diagnostics: current and emerging applications in oncology.

    abstract::Liquid biopsy is a noninvasive dynamic approach for monitoring disease over time. It offers advantages including limited risks of blood sampling, opportunity for more frequent sampling, lower costs and theoretically non-biased sampling compared with tissue biopsy. There is a high degree of concordance between circulat...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2018-0174

    authors: Muluhngwi P,Valdes R Jr,Fernandez-Botran R,Burton E,Williams B,Linder MW

    更新日期:2019-04-01 00:00:00

  • Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment.

    abstract:AIM:The activity of several key enzymes involved in the metabolism of many drugs is subject to change closely related to the age of patients. This possibility must also be considered in the case of tacrolimus, the most important calcineurins inhibitor, which is widely used in pediatric kidney transplantation. As well a...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.18

    authors: Ferraresso M,Turolo S,Belingheri M,Tirelli AS,Cortinovis I,Milani S,Edefonti A,Ghio L

    更新日期:2015-01-01 00:00:00

  • Applicability of gene expression and systems biology to develop pharmacogenetic predictors; antipsychotic-induced extrapyramidal symptoms as an example.

    abstract::Pharmacogenetics has been driven by a candidate gene approach. The disadvantage of this approach is that is limited by our current understanding of the mechanisms by which drugs act. Gene expression could help to elucidate the molecular signatures of antipsychotic treatments searching for dysregulated molecular pathwa...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.15.134

    authors: Mas S,Gassó P,Lafuente A

    更新日期:2015-11-01 00:00:00

  • HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients.

    abstract:AIM:Several HLA alleles have been associated with antiepileptic drugs (AEDs)-induced cutaneous adverse drug reactions (cADRs) in different populations; however, this has not been investigated in Mexican Mestizos (MM). Thus, the purpose of this preliminary study was to determine the association of HLA class I alleles wi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.135

    authors: Fricke-Galindo I,Martínez-Juárez IE,Monroy-Jaramillo N,Jung-Cook H,Falfán-Valencia R,Ortega-Vázquez A,Alonso-Vilatela ME,López-López M

    更新日期:2014-01-01 00:00:00

  • Rethinking ovarian cancer genomics: where genome-wide association studies stand?

    abstract::Genome-wide association studies (GWAS) allow the finding of genetic variants associated with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since 2009, with the discovery of 49 SNPs associated with disease susceptibility and 46 with impact in the clinical outcome of patients (p < 5.00 × 10-...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2017-0108

    authors: Pinto R,Assis J,Nogueira A,Pereira C,Pereira D,Medeiros R

    更新日期:2017-11-01 00:00:00

  • ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations.

    abstract::COVID-19 utilizes the ACE2 pathway as a means of infection. Early data on COVID-19 suggest heterogeneity in the severity of symptoms during transmission and infection ranging from no symptoms to death. The source of this heterogeneity is likely multifaceted and may have a genetic component. Demographic and clinical co...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2020-0048

    authors: Snyder EM,Johnson BD

    更新日期:2020-07-01 00:00:00

  • Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study.

    abstract:BACKGROUND:Essential hypertension arises from the combined effect of genetic and environmental factors. A pharmacogenomics approach could help to identify additional molecular mechanisms involved in its pathogenesis. AIM:The aim of SOPHIA study was to identify genetic polymorphisms regulating blood pressure response t...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.119

    authors: Frau F,Zaninello R,Salvi E,Ortu MF,Braga D,Velayutham D,Argiolas G,Fresu G,Troffa C,Bulla E,Bulla P,Pitzoi S,Piras DA,Glorioso V,Chittani M,Bernini G,Bardini M,Fallo F,Malatino L,Stancanelli B,Regolisti G,Ferri

    更新日期:2014-09-01 00:00:00

  • SimuGen Ltd: reliable, early prediction of drug toxicity with toxicogenomics, human cell culture and computational models.

    abstract::Toxicogenomics is, arguably, the most exciting endeavor to better understand and/or predict the toxicity of drugs during their development, using technologies such as gene-expression microarrays. Through much of its (sometimes overzealous) build-up, toxicogenomics has found a natural niche as a bioinformatics and/or p...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.8.1081

    authors: Wills Q

    更新日期:2007-08-01 00:00:00

  • Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.

    abstract::While antidepressants are widely used to treat mood and anxiety disorders, only half of the patients will respond to antidepressant treatment and only one-third of patients experience a full remission of symptoms. The identification of genetic biomarkers that predict antidepressant-treatment response can improve curre...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.12.1

    authors: Narasimhan S,Lohoff FW

    更新日期:2012-03-01 00:00:00

  • Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

    abstract:AIM:Our objective was to describe the association between voriconazole concentrations and CYP2C19 diplotypes in pediatric cancer patients, including children homozygous for the CYP2C19*17 gain-of-function allele. MATERIALS & METHODS:A linear mixed effect model compared voriconazole dose-corrected trough concentrations...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.53

    authors: Hicks JK,Crews KR,Flynn P,Haidar CE,Daniels CC,Yang W,Panetta JC,Pei D,Scott JR,Molinelli AR,Broeckel U,Bhojwani D,Evans WE,Relling MV

    更新日期:2014-06-01 00:00:00

  • Interpreter of maladies: redescription mining applied to biomedical data analysis.

    abstract::Comprehensive, systematic and integrated data-centric statistical approaches to disease modeling can provide powerful frameworks for understanding disease etiology. Here, one such computational framework based on redescription mining in both its incarnations, static and dynamic, is discussed. The static framework prov...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.3.503

    authors: Waltman P,Pearlman A,Mishra B

    更新日期:2006-04-01 00:00:00

  • Genetics of chronic obstructive pulmonary disease: a succinct review, future avenues and prospective clinical applications.

    abstract::Chronic obstructive pulmonary disease (COPD) is influenced by genetic and environmental factors. A large number of candidate gene-association studies and genome-wide linkage scans have been conducted to elucidate the genetic architecture underlying this disease. The compilation of these studies clearly revealed the co...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.10

    authors: Bossé Y

    更新日期:2009-04-01 00:00:00

  • Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.

    abstract:AIM:A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation. PATIENTS & METHODS:A PPK model was developed from 36 patients by a one-compartment model with first-order elimi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.98

    authors: Choi B,Kim MG,Han N,Kim T,Ji E,Park S,Kim IW,Oh JM

    更新日期:2015-01-01 00:00:00

  • Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial.

    abstract:AIM:This study aimed to assess the effectiveness of genotype-guided warfarin dosing. PATIENTS & METHODS:A total of 109 adults were randomized to receive initial dosing as determined by an algorithm containing genetic (VKORC1 and CYP2C9) plus clinical information or only clinical information. Primary end points were th...

    journal_title:Pharmacogenomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2217/pgs.13.145

    authors: Jonas DE,Evans JP,McLeod HL,Brode S,Lange LA,Young ML,Shilliday BB,Bardsley MM,Swinton-Jenkins NJ,Weck KE

    更新日期:2013-10-01 00:00:00

  • Integrating heterogeneous high-throughput data for meta-dimensional pharmacogenomics and disease-related studies.

    abstract::The current paradigm of human genetics research is to analyze variation of a single data type (i.e., DNA sequence or RNA levels) to detect genes and pathways that underlie complex traits such as disease state or drug response. While these studies have detected thousands of variations that associate with hundreds of co...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.11.145

    authors: Holzinger ER,Ritchie MD

    更新日期:2012-01-01 00:00:00

  • Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.

    abstract::Interferon-β (IFN-β) and glatiramer acetate are routinely used to inhibit disease activity in multiple sclerosis, but their mechanisms of action are incompletely understood. Individual treatment responses vary and candidate molecular markers that predict them have yet to be established. Why some patients respond poorl...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.10.190

    authors: Goertsches RH,Zettl UK,Hecker M

    更新日期:2011-03-01 00:00:00

  • Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.

    abstract:OBJECTIVE:We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. METHODS:A total of 45 heavi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.8.4.319

    authors: Vincenzi B,Santini D,Russo A,Gavasci M,Battistoni F,Dicuonzo G,Rocci L,Rosaria VM,Gebbia N,Tonini G

    更新日期:2007-04-01 00:00:00

  • Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications.

    abstract::Second-generation antipsychotics can greatly improve symptoms of psychosis-spectrum disorders. Unfortunately, these drugs are associated with weight gain, which increases a patient's risk for developing chronic diseases including Type 2 diabetes, cardiovascular diseases or other obesity-related complications. There ar...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.11.45

    authors: Lee AK,Bishop JR

    更新日期:2011-07-01 00:00:00

  • Genomics, complexity and drug discovery: insights from Boolean network models of cellular regulation.

    abstract::The completion of the first draft of the human genome sequence has revived the old notion that there is no one-to-one mapping between genotype and phenotype. It is now becoming clear that to elucidate the fundamental principles that govern how genomic information translates into organismal complexity, we must overcome...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.2.3.203

    authors: Huang S

    更新日期:2001-08-01 00:00:00

  • Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report.

    abstract::We report the case of a patient bearing a T315I-mutant chronic myeloid leukemia resistant to nilotinib, successfully treated with omacetaxine and then with dasatinib. After 9 months of nilotinib, the patient achieved a major molecular response but relapsed 3 months later due to the T315I mutation. Because third-genera...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.25

    authors: Venton G,Colle J,Mercier C,Fanciullino R,Ciccolini J,Ivanov V,Suchon P,Sebahoun G,Beaufils N,Gabert J,Hadjaj D,Costello R

    更新日期:2015-01-01 00:00:00

  • The current and future state of pharmacogenomics medical education in the USA.

    abstract::Healthcare professionals (e.g., physicians, physician assistants, pharmacists, nurses and genetic counselors) believe pharmacogenomics (PGx) is essential to personalized medicine; however, they still lack confidence prescribing, dosing, interacting with other healthcare professionals and counseling patients with regar...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.12.113

    authors: Nickola TJ,Green JS,Harralson AF,O'Brien TJ

    更新日期:2012-09-01 00:00:00

  • SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.

    abstract:AIM:Based on previous pharmacogenetic findings, we investigated the possible association between SULT4A1-1 haplotype and antipsychotic treatment response. MATERIALS & METHODS:Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Po...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.105

    authors: Wang D,Li Q,Favis R,Jadwin A,Chung H,Fu DJ,Savitz A,Gopal S,Cohen N

    更新日期:2014-01-01 00:00:00

  • Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response.

    abstract:AIM:To investigate the role of genetic polymorphisms in glutamatergic and GABAergic genes and their interactions with environmental stressors in antidepressant response. METHODS:A set of 114 SNPs of 34 glutamatergic and GABAergic genes, mainly in promoter and coding regions, were genotyped in 281 Chinese Han major dep...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.1

    authors: Pu M,Zhang Z,Xu Z,Shi Y,Geng L,Yuan Y,Zhang X,Reynolds GP

    更新日期:2013-02-01 00:00:00

  • Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia.

    abstract::Childhood acute lymphoblastic leukemia survival rates have increased remarkably during last decades due, in part, to intensive treatment protocols. However, therapy resistance and toxicity are still two important barriers to survival. In this context, pharmacoepigenetics arises as a tool to identify new predictive mar...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2017-0164

    authors: Umerez M,Garcia-Obregon S,Martin-Guerrero I,Astigarraga I,Gutierrez-Camino A,Garcia-Orad A

    更新日期:2018-03-01 00:00:00

  • MicroRNAs and pharmacogenomics.

    abstract::Pharmacogenomics studies the influence of genomics on drug response safety and efficacy. Although research in this field was initiated many years ago, few functional applications are currently in use at the clinic. MicroRNAs (miRNAs) are short noncoding RNAs that bind genes and silence their expression. MiRNAs are enc...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.10.26

    authors: Shomron N

    更新日期:2010-05-01 00:00:00